This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.
The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.
FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Despite the overall survival benefit associated with fruquintinib, weighing the risks and benefits of the drug remains important; and one oncologist questioned the trial s placebo arm.